Although drugs of abuse have different chemical structures and interact with different protein targets, all appear to usurp common neuronal systems that regulate reward and motivation. Addiction is a complex disease that is thought to involve drug-induced changes in synaptic plasticity due to alterations in cell signaling, gene transcription, and protein synthesis. Recent evidence suggests that drugs of abuse interact with and change a common network of signaling pathways that include a subset of specific protein kinases. The best studied of these kinases are reviewed here and include extracellular signal-regulated kinase, cAMP-dependent protein kinase, cyclin-dependent protein kinase 5, protein kinase C, calcium/calmodulin-dependent protein kinase II, and Fyn tyrosine kinase. These kinases have been implicated in various aspects of drug addiction including acute drug effects, drug self-administration, withdrawal, reinforcement, sensitization, and tolerance. Identifying protein kinase substrates and signaling pathways that contribute to the addicted state may provide novel approaches for new pharmacotherapies to treat drug addiction.
Introduction
The development of addiction involves pathological drug-induced changes in cellular and molecular mechanisms of synaptic plasticity that underlie normal learning and memory. [1] [2] [3] Common neuronal pathways and molecular adaptations to different drugs of abuse in the limbic system have been identified. 4 Recently, a large genetic meta-analysis has identified some common genes and signaling pathways in drug addiction, and protein kinases are central components in this postulated common molecular network. 5 Abused drugs stimulate signaling pathways that activate protein kinases, leading to altered gene transcription and protein synthesis, which contribute to long-term changes in synaptic func-tion and neural networks that ultimately result in addiction. Here we review some of the beststudied protein kinases that appear to be pivotal in addiction: extracellular signal-regulated kinase, cAMP-dependent protein kinase, cyclindependent protein kinase 5, protein kinase C, calcium/calmodulin-dependent protein kinase II, and Fyn tyrosine kinase. These protein kinases are all widely expressed throughout the brain and in the limbic system. 6 Addictive substances can be generally grouped into drugs that interact with monoamine transporters, activate G i/o -coupled protein receptors, or alter the function of ion channels and ionotropic receptors. 7 The psychostimulants cocaine and amphetamines both increase extracellular levels of monoamines, such as dopamine, but they act through different molecular mechanisms: cocaine inhibits the cell surface dopamine transporter (DAT), while amphetamines inhibit DAT and also stimulate dopamine release from vesicles allowing reverse transport of dopamine through DAT. Nicotine also has stimulatory effects through activation of nicotinic acetylcholinergic (nACh) receptors, which are ligand-gated cation channels. Opiates and cannabinoids activate different G i/ocoupled protein receptors and appear to activate some similar downstream signaling events. Ethanol alters the function of several ion channels and ionotropic receptors and often produces different effects compared with other addictive drugs. We will examine the effects of cocaine, amphetamines, nicotine, opiates, cannabinoids, and ethanol on protein kinases, summarizing the available studies. Importantly, we will also review the effects of manipulating protein kinases in animal models with an emphasis on identifying signaling pathways that could provide new targets for treatment of addiction.
Extracellular Signal-Regulated Kinases
ERKs are serine-threonine protein kinases that are members of the mitogen-activated protein kinase (MAPK) family. Two isoforms have been identified, p44 ERK1 and p42 ERK2, which share similar, though not identical, functions. ERKs are involved in many aspects of neuronal function including control of cell growth, cell differentiation, neuronal survival, and synaptic plasticity. [8] [9] [10] ERK1 and ERK2 are widely expressed throughout the brain, including in the mesolimbic dopaminergic system. Both are strongly expressed in the amygdala and prefrontal cortex and moderately expressed in the ventral tegmental area (VTA), nucleus accumbens (NAc), and midbrain. 6 ERKs are activated by a Ras-Raf-MEK signaling cascade that involves sequential phosphorylation of upstream kinases. Several growth factors such as the brain-derived neurotrophic factor (BDNF) activate receptor tyrosine kinases that recruit the adapter proteins Grb2 and Shc, in turn leading to activation of the GTPase Ras. Ras can also be activated by cal-cium influx through L-type calcium channels or NMDA receptors through stimulation of Ras protein-specific guanine-nucleotide releasing factor (Ras-GRF1), a Ca 2+ -activated guanine nucleotide exchange factor expressed in neurons of the central nervous system. 11 Ca 2+ influx can be enhanced by G s -coupled neurotransmitter receptors such as the dopamine D1 receptor, which increase protein kinase A (PKA)-mediated phosphorylation and ion channel function. 12 Activated Ras in turn activates Raf, which phosphorylates and activates MAPK/ERK kinases (MEK1 and MEK2) that phosphorylate and activate the ERKs. 13 ERK activity is also modulated by other signal transduction molecules, such as PKA and dopamine-and cAMP-regulated phosphoprotein of 32kDa (DARPP-32, also called PPP1R1B; protein phosphatase 1, regulatory [inhibitor] subunit 1B), 12 (Fig. 1 ) as discussed later. As ERK activity is regulated by dopamine and glutamate receptor stimulation and incorporates signals from many second messenger pathways, ERKs may function as coincidence detectors that combine rewards and contextual information in learning processes. 8 Thus, ERK activity has been proposed to play integrative roles in the development of drug addictions.
Downstream targets of ERKs include transcription factors and immediate early genes that play roles in mediating drug-induced synaptic plasticity, including ribosomal S6 kinase (RSK) and mitogen-and stress-stimulated kinase 1 (MSK1). These downstream kinases phosphorylate and activate the cAMP response element binding protein (CREB). ERKs also can directly phosphorylate the Elk-1 transcription factor. Activation of CREB and Elk-1 can lead to the transcription of the immediate early genes c-fos and zif268, which are induced by several drugs of abuse. 2 
Effects of Addictive Drugs on ERK Signaling
Administration of addictive drugs to rats and mice can activate ERK in many of the Cannabinoid CB1 receptors and opioid receptors also activate G i/o . Gα s and Gβγ released from G i/o activate adenylyl cyclase, leading to increased cAMP levels which activate PKA. Induction of the transcription factor deltaFosB increases Cdk5 expression. Differential phosphorylation of DARPP-32 by PKA and Cdk5 inhibits or facilitates PKA signaling. Gβγ also activates GIRK channels leading to inhibition of excitability. Gα q and Gβγ activate PLC and PLD, leading to the activation of PKC. Several downstream PKA and PKC targets are listed at the bottom. Activation of ionotropic glutamate receptors and L-type calcium channels increases intracellular calcium levels, leading to activation of the Ras-Raf-MEK-ERK pathway. Activation of TrkB receptors also activates the ERK pathway, leading to the phosphorylation of transcription factors CREB and Elk-1. Examples of cross-talk between the PKA, PKC, Cdk5, and ERK signaling pathways are illustrated. This diagram is a simplification that does not incorporate differential expression of kinases in different brain regions and cell types. brain regions that constitute or are targets of the mesolimbic dopaminergic system, including the VTA, NAc, prefrontal cortex, bed nucleus of the stria terminalis (BNST), and the amygdala. 14, 15 ERK activation can be measured as a drug-induced increase in phosphorylated ERK protein (p-ERK) that can be blocked by selective MEK inhibitors, such as U0126, SL327, or PD98059, which prevent ERK activation. Acute cocaine treatment transiently increases p-ERK throughout the stria-tum through a mechanism that involves activation of D1 dopamine and NMDA receptors. This increase in p-ERK can be blocked by systemic injection of SL327. 16, 17 SL327 also inhibits cocaine-induced c-fos expression and Elk-1 hyperphosphorylation. Acute and repeated administration of cocaine also increases p-ERK in the prefrontal cortex, BNST, and amygdala. In the VTA, cocaine increases levels of p-ERK, but only after repeated administration. 18 Unlike cocaine, amphetamine acutely increases p-ERK in the VTA, 19 and like cocaine, it increases p-ERK in the dorsal striatum 20, 21 and NAc. 22 Amphetamine also induces striatal expression of preproenkephalin and preprodynorphin through an ERK-dependent mechanism, since this response is attenuated by systemic or intrastriatal injection of MEK inhibitors. 20 Nicotine, like cocaine, also increases p-ERK in the prefrontal cortex and amygdala. 23 Acute administration of delta (9)tetrahydrocannabinol (THC), the major active compound in marijuana, also increases ERK phosphorylation in the dorsal striatum, in ways that parallel effects of stimulants. Unlike stimulants, THC increases ERK phosphorylation in the cerebellum as well. 24, 25 ERK phosphorylation is also increased by acute administration of opiates. Morphine increases p-ERK in the VTA 18 and cerebral cortex. 26 In general, stimulants, cannabinoids, and opiates increase p-ERK levels in a distinctive pattern that includes the NAc, lateral bed nucleus of the stria terminalis, central amygdala, and deep layers of the prefrontal cortex. 14 Inhibition of MEK prevents these drug-induced increases in p-ERK. 20, 25 In contrast to drugs listed above, ethanol inhibits ERK phosphorylation. Acute administration of alcohol decreases levels of p-ERK in the amygdala, dorsal striatum, cerebellum, cerebral cortex, and hippocampus. [27] [28] [29] The mechanism by which ethanol reduces ERK phosphorylation is unknown. However, in rats treated chronically with ethanol, hepatic ERK phosphorylation is decreased in association with elevated levels of the lipid peroxidation product 4-hydroxynonenal, which inhibits ERK phosphorylation in vitro. 30 ERK activation and the downstream changes in transcription evoked by stimulant drugs and cannabinoids are dependent on the activation of dopamine and NMDA receptors. Dopamine antagonists prevent the increases in ERK phosphorylation that result from cocaine, 16 amphetamine, 21 methamphetamine, 31 or THC administration. 32 Dopamine D1 receptor knockout mice fail to display druginduced increases in p-ERK 17, 33 or ERKdependent increases in phosphorylated CREB (p-CREB) 33 or c-fos levels. 17 Inhibition of NMDA receptors also prevents the ERK phosphorylation that results from treatment with cocaine, 33 amphetamine, 21 THC, 32 or the cannabinoid receptor 1 (CB1) agonist WIN-55212-2. 34 The effect of THC on ERK is mediated through Ras. Knockout mice lacking Ras-GRF1 do not show THC-mediated increases in p-ERK in the dorsal striatum or cerebellum. 24 Studies with MEK inhibitors indicate that several drugs of abuse regulate the activity of transcription factors and increase gene expression through ERK-dependent mechanisms. For example, cocaine increases c-fos mRNA and phosphorylation of Elk-1, and these effects are inhibited by the MEK inhibitor SL327. 16 SL327 also inhibits increases in c-fos and egr-2 mRNA induced by methamphetamine, 35 and increases in proenkephalin and preprodynorphin mRNA induced by amphetamine. 20 THC increases Elk-1 phosphorylation and levels of zif268 mRNA levels, and these increases are inhibited by SL327 as well. 32 Drug-stimulated ERK activity is regulated by dephosphorylation through a network of phosphatases whose activities are regulated by PKA. 36 The striatal-enriched protein tyrosine phosphatase (STEP; PTPN5 protein tyrosine phosphatase, nonreceptor type 5 striatumenriched) inactivates ERK by dephosphorylating a tyrosine residue within its activation loop. The ability of STEP/PTPN5 to dephosphorylate ERK is lost by PKAmediated phosphorylation of STEP/PTPN5 at a regulatory serine within its ERK-binding domain. This serine can be dephosphorylated by protein phosphatase 1 (PP1), and PKA-phosphorylated DARPP-32 inhibits PP1. Therefore, in the absence of DARPP-32 inhibition, PP1 can dephosphorylate STEP/PTPN5, allowing it to bind, dephosphorylate, and inactivate ERK. In addition to suppressing STEP activity, DARPP-32 also mediates drug-induced increases in ERK activity by promoting the phosphorylation and activation of MEK. These mechanisms explain why in DARPP-32 knockout mice, cocaine, amphetamine, nicotine, THC, or morphine fail to increase ERK phosphorylation in the NAc. 21 Calcium/calmodulin-dependent protein kinases (CaMKs) also regulate activation of ERK by drugs of abuse. KN93, which inhibits type II CaMK (CaMKII), prevents nicotinemediated increases in p-ERK in mouse cortical neurons. 37 Inhibition of CaMKI and its upstream activator CaMK kinase prevents NMDA-mediated increases in p-ERK in mouse hippocampal neurons. 38 Given the role of NMDA receptors in drug-induced ERK activation, it is possible that CaMKI is also involved in the activation of ERK by drugs of abuse.
ERK in Addiction-Related Behaviors

Sensitization
Depending on the dose, acute exposure to many addictive drugs increases or decreases motor activity. Repeated drug administration in specific patterns can produce psychomotor sensitization, an increase in locomotor activity, or stereotypy that has been observed with stimulants 39 and alcohol. 40 Psychomotor sensitization is associated with increased drug reward, 41 relapse, 42 and consumption 43 in rodents. Pretreatment of rodents with systemic SL327 prevents the hyperlocomotion induced by acute injections of cocaine, 44 amphetamine, 20, 44 and methamphetamine. 35 The development of psychomotor sensitization is prevented by pretreatment with intra-VTA injections of SL327 in rats given repeated injections of cocaine 45 and by systemic pretreatment with SL327 in mice given repeated injections of amphetamine. 21 These data indicate that ERK activity is necessary for the expression of hyperlocomotion and for the psychostimulant induction of psychomotor sensitization.
Drug Tolerance
Tolerance can occur with repeated drug administration. The development of tolerance to the hedonic effects of drugs may favor escalation of drug consumption and development of addiction. 46 Instead of hyperlocomotion, acute cannabinoid treatment produces hypolocomotion in rodents. Pretreatment with systemic SL327 does not prevent the development of hypolocomotion induced by acute THC injections. Such pretreatments do prevent the development of tolerance to the hypolocomotor effects of repeated THC injection in mice. 25 In summary, ERK activity appears to be important for the expression of hyperlocomotor activity from acute administration of many addictive drugs, the development of psychomotor sensitization to psychostimulants, and the development of tolerance to the hypolocomotor effects of cannabinoids.
Drug Withdrawal and Relapse
Addiction is associated with a high risk of relapse long after physical signs of withdrawal have ceased. Relapse can occur after years of abstinence. Cues previously associated with a drug may trigger relapse even after a lengthy period of abstinence. In rat models of drug self-administration followed by prolonged withdrawal (30 days), the presentation of cues previously associated with cocaine 47 or alcohol 48 can increase levels of p-ERK in the amygdala. Administration of an NMDA receptor antagonist decreases p-ERK and drug-seeking behavior, suggesting that p-ERK facilitates cocaine seeking through an NMDA-dependent mechanism. 47,49
Incubation of Drug Craving
The "incubation" of drug craving is a phenomenon whereby cue-induced drug-seeking progressively increases over time during withdrawal. After rats undergo repeated selfadministration sessions (for instance, 6 h of cocaine self-administration daily for 10 days), during which cocaine is associated with discrete cues, subsequent cue-induced drug-seeking (nonreinforced responding on the previously active lever) increases over time. Responses are significantly higher after 30 days of cocaine withdrawal than after short-term withdrawal (1-7 days). 47,50 This time-dependent increase in responding is associated with increased p-ERK in the central amygdala 47 and increased levels of BDNF in the VTA, NAc, and amygdala. 50 These increases in BDNF and p-ERK appear to facilitate drug seeking. Thus, BDNF infusions into the VTA increase cue-induced drug seeking for up to 30 days after cocaine withdrawal. 51 This effect of BDNF is ERK dependent since it is reversed by intra-VTA infusions of the MEK inhibitor U0126. 51 Even in the absence of BDNF infusion, U0126 injections into the central amygdala decrease drug seeking during cocaine withdrawal, 47 indicating that ERK activity in the central amygdala is required for drug-seeking during cocaine withdrawal. 47 This requirement is specific for cue-induced cocaine seeking but not for reinforced responding. Microinjection of U0126 into the amygdala does not reduce selfadministration of cocaine or consumption of palatable foods. 47
Conditioned Place Preference
Conditioned place preference (CPP) is a conditioning procedure whereby an animal is injected with a drug in one environmental context and with vehicle in another context (the conditioning phase). After conditioning, the animal is then tested for CPP expression by allowing it to choose between drug-and vehicle-paired contexts. If the animal spends more time in the drug-paired context, the drug is thought to be rewarding. Activation of ERK is necessary for the development of drug-induced CPP. Pretreatment with systemic injections of SL327 during the conditioning phase prevents the development of cocaine-, 16 methamphetamine-, 35 THC-, 32 and morphine-induced CPP. 44 A different MEK inhibitor, PD98059, infused directly into the NAc, also inhibits the development of methamphetamine-induced CPP. 22 Established cocaine CPP increases phosphorylation of ERK, CREB, and Elk-1 in the rat NAc. These changes are attenuated by intra-VTA injections of U0126. 52 Thus ERK activity appears to be involved in mediating the rewarding properties of psychostimulants, cannabinoids, and opiates.
Memory Reconsolidation
When long-term memories are retrieved, they are transiently labile and susceptible to modification by environmental stimuli through a process called reconsolidation. 53 The memory of an environmental cue associated with an addictive drug is subject to reconsolidation that is dependent on ERK activity. In rats trained to develop cocaine CPP, an injection of U0126 into the NAc core immediately after CPP testing prevents subsequent expression of CPP on retesting. 52 The specific retrieval of the longterm memory is crucial for MEK inhibition to affect this memory. Rats treated with U0126 without a prior CPP test that would retrieve the long-term association did not show a deficit in CPP expression in subsequent tests. 52 MEK inhibition also affects CPP memory reconsolidation for other addictive drugs. PD98059 injections into the VTA inhibit reconsolidation of methamphetamine CPP. 31 Systemic SL327 injections inhibit reconsolidation of morphine CPP 44 in rodents. ERK activation ultimately results in increased protein synthesis. Inhibition of protein synthesis using systemic anisomycin during long-term memory retrieval also impairs reconsolidation of cocaine 44 and morphine CPP. 54 In addition to CPP reconsolidation, ERK activation is crucial for the reconsolidation of other forms of memory. Inhibition of MEK with U0126 injections into the lateral nucleus of the amygdala inhibits reconsolidation of auditory fear conditioning. 55 Intracerebroventricular injection of U0126 inhibits reconsolidation of object recognition. 56 
Differential Effects of ERK1 and ERK2 in Responses to Drugs of Abuse
Current MEK inhibitors do not distinguish between ERK1 and ERK2. However, studies with ERK1 knockout mice suggest that ERK1 and ERK2 play different roles in some responses to addictive drugs. ERK1 knockout mice show increased ERK2-mediated signaling. 57 These mice also show enhanced development of cocaine-induced psychomotor sensitization 58 and much greater cocaine-58 and morphine-induced CPP than wild-type mice. 57 In addition, place conditioning for cocaine increases phosphorylation of ERK2 but not ERK1 in the rat NAc. 52 These results suggest that ERK2 might be the more important ERK isoform in mediating drug-induced CPP and sensitization to cocaine.
cAMP-Dependent Protein Kinase
PKA is multifunctional and is involved in many aspects of neuronal function including synaptic plasticity, 59,60 exocytosis, 61 and gene transcription. 62 PKA can also modulate other second-messenger pathways such as the MAPK signaling pathway. 60 PKA is expressed throughout the brain, where it is particularly abundant in the cortex, thalamus, and amygdala and moderately abundant in the midbrain, NAc, and VTA. 6 PKA is a tetramer comprising two regulatory subunits and two catalytic subunits. There are four regulatory subunit isoforms (RIα, RIβ, RIIα, RIIβ) and three catalytic isoforms (Cα, Cβ, Cγ); all are widely expressed in the brain. 59 As a tetramer, PKA is inactive. Cyclic adenosine 3 , 5 -monophosphate (cAMP), produced by adenylyl cyclase, activates PKA by binding to the regulatory subunits in ways that result in the release and nuclear translocation of active catalytic subunits. 63 PKA activity can be measured as increased PKA catalytic subunit translocation 63 or as increased PKA-mediated phosphorylation of specific substrates such as the α-amino-3-hydroxy-5methyl-isoxazolepropionic acid (AMPA) receptor GluR1 subunit Ser-845 64 or the NMDA receptor NR1 subunit Ser-897. 65 Activation of PKA is dependent on cAMP produced by the activation of one or more of the nine isoforms of adenylyl cyclase that are activated or inhibited in complex manners by G-proteins. 66 All adenylyl cyclases are activated by Gα s . AC5 is activated by Gα olf ; AC2, AC4, and AC7 are activated by free Gβγ subunits released from G i/o ; and AC1, AC5, AC6, and AC8 are inhibited by Gα i/o . Addictive drugs acutely increase levels of extracellular dopamine in the NAc, 4 activating adenylyl cyclase and PKA via stimulation of G sand G olf -coupled D1 receptors. 67 Dopamine also activates D2 receptors coupled to G o , leading to inhibition of several adenylyl cyclase isoforms. Dopamine activation of D2 receptors releases Gβγ subunits, which exert multiple effects that include enhancement of AC2 and AC4 activation, stimulation of G proteinregulated inwardly rectifying K + (GIRK) channels, and inhibition of L-, N-, and P/Q-type calcium channels. In addition to stimulating dopamine release in the striatum, opiates can activate adenylyl cyclase by binding to opioid receptors that couple to G i/o . 68 The net effect of Gβγ on ion channel function is well established and results in decreased neuronal excitability and neurotransmitter release. 67 Gβγ-mediated enhancement of adenylyl cyclase activity by G i/o -coupled receptors has been documented in vitro and may contribute to signaling in the NAc. Increased firing of accumbal neurons upon co-activation of D1 and D2 receptors appears to involve Gβγ stimulation of adenylyl cylcase. 69 Finally, adenylyl cyclases can be modulated by protein kinases, including protein kinase C (PKC), which activates AC2, AC4, and AC7. 66 One important downstream regulator of dopaminergic signaling is DARPP-32. DARPP-32 is highly expressed in striatal neurons 70 and can act as a protein kinase inhibitor or a protein phosphatase inhibitor, depending on the site of DARPP-32 phosphorylation. When PKA phosphorylates DARPP-32 on Thr-34, it serves as an inhibitor of PP-1. 71 Activation of dopaminergic signaling by electrical stimulation of mouse striatal slices or by acute systemic injections of cocaine in mice increases PKA-mediated phosphorylation of DARPP-32 on Thr-34, which then inhibits PP-1 mediated dephosphorylation of PKA substrates, 72 effectively amplifying dopamine-stimulated phosphorylation by PKA. Cyclin-dependent protein kinase 5 (Cdk5, discussed in the next section) phosphorylates DARPP-32 at a different site. This Thr-75 phosphorylation renders DARPP-32 an inhibitor of PKA 73 and antagonizes several effects of dopamine in the striatum.
PKA phosphorylates NR1 subunits, 65 which leads to increased NMDA receptor function. 74 Activation of dopamine D1 receptors induces PKA-mediated phosphorylation of NR1 subunits and subsequent phosphorylation and activation of the transcription factor CREB in rat striatal neurons. 75 D1 receptor-mediated CREB phosphorylation is blocked by the NMDA receptor antagonist MK801 but not by either of the MEK inhibitors PD98059 or U0126. 75 However, PKA can indirectly activate ERK by facilitating the activation of B-Raf through the small G-protein Rap1; B-Raf then phosphorylates and activates MEK. 60 Thus, activation of α7 nACh receptors by nicotine stimulates the ERK pathway in a PKA-dependent manner in mouse hippocampal neurons. 76 PKA can contribute to drug-induced synaptic plasticity. PKA phosphorylates GluR1 subunits of AMPA receptors, which promotes AMPA receptor trafficking to the cell surface. 77 Dopamine D1 receptor agonists, SKF81297 and SCH23390, and the PKA activator Sp-cAMPS increase GluR1 cell surface expression in the NAc 78 and the hippocampus of rats. 79 Drug-induced activation of PKA can thus increase synaptic strength, measured electrophysiologically as an increase in the ratio of AMPA-to NMDA-mediated current. This provides a mechanism for drug-induced synaptic plasticity. In addition to AMPA currents, PKA can also regulate NMDA-stimulated currents. In rat midbrain slices, acute treatment with cocaine produces a delayed increase in NMDA-mediated currents in VTA dopaminergic neurons that is blocked by the PKA in-hibitor Rp-cAMPS and by D1/D5 receptor antagonists. 80 
Effects of Addictive Drugs on PKA Signaling
Acute administration of psychostimulants increases PKA activity and PKA-mediated phosphorylation of downstream targets. In rodents, acute injections of cocaine increase PKA-mediated phosphorylation of DARPP-32, NR1, and GluR1 in the medial prefrontal cortex and NAc, 81 as well as phosphorylation of DARPP-32 in the striatum. 72 Acute administration of cocaine in mice can increase PKAmediated activation of protein phosphatase 2A (PP-2A), which then dephosphorylates DARPP-32 at the Cdk5-mediated phosphorylation site (Thr-75), promoting PKA-mediated signaling. 72 The effect of chronic cocaine on PKA signaling depends on the species examined. In rats, chronic exposure to cocaine increases the level of Cdk5 in the striatum, attenuating the effects of PKA 82 (discussed in the next section). However, chronic treatment of monkeys with cocaine for one year upregulates PKA catalytic subunit mRNA and protein in the NAc, 83 suggesting that there may be an overall upregulation of PKA activity in primate NAc by prolonged exposure to cocaine.
In vitro, acute treatment of mouse striatal neurons with nicotine has different effects on PKA activity depending on the nicotine dose. Acute, low doses of nicotine decrease PKA-mediated DARPP-32 phosphorylation, primarily by activating dopamine D2 receptors. 84 High doses of nicotine increase PKA-mediated DARPP-32 phosphorylation, mainly by activating D1 receptors. 84 In rats treated with nicotine for 14 days, PKA activity is decreased in whole brain homogenates, 85 suggesting that chronic nicotine exposure decreases PKA activity in the brain. However, postmortem studies have shown that smokers and former smokers have higher PKA activity and PKA catalytic subunit protein levels in the NAc and ventral midbrain than do nonsmokers. 86 These results indicate that prolonged smoking in humans, similar to chronic cocaine treatment in monkeys, 83 may upregulate PKA activity in some brain regions that are important for addiction.
Cannabinoids and opiates can increase PKA activity via dopaminergic stimulation of adenylyl cyclase. Acute treatment with CB1 agonists increases PKA activity in mouse striatum 87, 88 and NAc. 88 This increased PKA activity is attenuated by antagonists of the CB1 87, 88 or D1 receptors. 88 The effect of chronic cannabinoid treatment is less clear-cut. Chronic treatment with THC in mice increases PKA activity in the cortex 89 but can both increase 89 and decrease PKA activity in the cerebellum. 90 Similar to cannabinoids, acute stimulation of μ-opioid receptors in rat striatal neurons in vitro increases nuclear translocation of the PKA catalytic subunit and increases levels of p-CREB. 68 Opiates can increase PKA signaling; this effect can be enhanced during opiate withdrawal. 91 Opiates increase PKAmediated phosphorylation in several brain regions including the NAc, 92,93 striatum, 92 hippocampus, 94, 95 and locus coeruleus, 96 but do not increase this phosphorylation in the frontal cortex. 97 In cultured striatal neurons, morphine activates PKA by activating μ-opioid receptors, leading to the release of Gβγ from G i3 , and subsequent activation of AC2 and AC4. 68 In vivo however, morphine-induced activation of PKA in the NAc and dorsal striatum requires activation of D1 receptors coupled to Gα s/olf since it is blocked by the D1 antagonist SCH23390. 92 Ethanol can increase PKA activity acutely by inhibiting adenosine reuptake through the type I equilibrative nucleotide transporter, which increases extracellular adenosine levels, activates G olf -coupled adenosine A2a receptors, stimulates adenylyl cyclase, and increases levels of cAMP. 98, 99 This process leads to nuclear translocation of the PKA catalytic subunit in NG108-15 neuroblastoma × glioma cells in vitro. 100 By contrast, chronic ethanol treatment in rats increases PKA activity in the cerebral cortex of rats. 101 Adenosine A2a receptors also mediate the synergistic activation of PKA by combined subthreshold doses of several addictive drugs. 102, 103 Cannabinoid and opioid receptor agonists can act together or with ethanol to activate PKA at doses that would not normally activate PKA when given alone. Adenosine A2a receptor antagonists block this effect. CB1 receptor agonists acutely increase PKA-dependent DARPP-32 phosphorylation at Thr-34 in mouse dorsal striatum and NAc. 88 This increase is blocked by administration of the A2a receptor antagonist KW6002. 88 Withdrawal from chronic drug exposure may induce PKA-mediated synaptic plasticity. In rats, prolonged withdrawal from chronic cocaine increases corticotropin releasing factor (CRF)-mediated long-term potentiation (LTP) in the central nucleus of the amygdala. This effect is significantly decreased by the PKA inhibitor H89. 104 Chronic opiate treatment depresses LTP in rat hippocampal CA1 neurons and increases PKA activity, which may represent compensatory actions since opioid receptors are coupled to inhibitory G i/o proteins. 95 After withdrawal from chronic opiate treatment, administration of PKA inhibitors or a single injection of morphine can reduce PKA levels and restore LTP. 95 These data suggest that PKA is involved in the enhancement of amygdala LTP noted during withdrawal from chronic cocaine and in the depression of hippocampal LTP noted during chronic opiate treatment.
PKA in Behavioral Responses
to Drugs of Abuse Sensitization PKA contributes to psychostimulantinduced locomotor sensitization. Intra-VTA injection of the PKA inhibitor Rp-cAMPS decreases amphetamine-induced locomotor sensitization. Sp-cAMPS, a PKA activator, increases amphetamine-induced locomotor sensitization in rats. 105 Intracerebroventricular injection of forskolin, which increases PKA activity by increasing production of cAMP, enhances cocaine-induced locomotor sensitization in rats. 106 
Drug Tolerance
Chronic treatment with cannabinoids and opiates results in tolerance to their analgesic effects through a mechanism that is mediated by PKA. Inhibition of PKA can restore analgesic sensitivity in tolerant animals. In mice tolerant to THC analgesia, intracerebroventricular injections of the PKA inhibitor KT5720 restore analgesic sensitivity. 107 In rats tolerant to morphine analgesia, intracerebroventricular injection of PKA antisense oligonucleotides blocks the development of tolerance. 108 Intracerebroventricular injections of the PKA inhibitors KT-5720 or 4-cyano-3-methylisoquinoline restore analgesic sensitivity. 109
Drug Self-Administration
Manipulation of PKA activity can increase or decrease the self-administration of addictive drugs in rodent models. The direction of the effect varies with the type of addictive drug. Decreasing PKA activity decreases psychostimulant self-administration in rodents. In rats trained to self-administer cocaine, intraaccumbal injections of the PKA inhibitor Rp-cAMPS decrease self-administration, whereas injections of the PKA activator Sp-cAMPS increase self-administration. 110 No change in self-administration is seen when Rp-cAMPS or Sp-cAMPS are injected into the caudateputamen, indicating that the effects of PKA on self-administration are selective for the NAc. 110 In progressive ratio paradigms that assess the extent of work that an animal is willing to perform for access to drug, intra-accumbal injections of Rp-cAMPS decrease the breaking point at which rats no longer lever press for cocaine, while Sp-cAMPS increases the breaking point. 111 This effect persists for at least 4 days after injection of the PKA modulator. 111 These data suggest that PKA in the rat NAc regulates motivation to self-administer cocaine.
PKA also modulates ethanol consumption. Activation of adenosine A2a receptors increases PKA activity. 66 Systemic injection of the A2a receptor antagonist 3,7-dimethylpropargylxanthine, which is predicted to decrease PKA activation mainly in the striatum where A2a receptors are highly expressed, 112 reduces ethanol self-administration in rats. 113 Mice that express a dominant negative form of PKA in the forebrain and hippocampus, and therefore have lower brain PKA activity in these areas, show reductions in both ethanol consumption and ethanol preference when compared with wild-type mice. 114 However, injection of the PKA inhibitor Rp-cAMPS into the rat central amygdala increases ethanol intake and preference, 115 in part by increasing anxiety-like behavior. 116 The effects of PKA on behavior thus display regional specificity within the brain.
Rats selected for high ethanol preference (ethanol-preferring "P" rats) show increased anxiety-like behavior and lower levels of p-CREB and neuropeptide Y in the central and medial amygdala when compared with ethanol-nonpreferring "NP" rats. 116 P rats show reduced anxiety after voluntary ethanol consumption, whereas NP rats do not. Injection of Sp-cAMPS into the central amygdala of P rats drives levels of ethanol intake, anxiety-like behavior, and amygdala p-CREB toward the lower levels found in NP rats. 116 Sp-cAMPS injection does not affect anxiety-like behavior in NP rats. Injection of Rp-cAMPS into the central amygdala of NP rats does increase ethanol consumption and anxiety-like behavior. 116 These data show that PKA modulation of ethanol drinking depends on interaction with alleles in P and NP rats that may also be responsible for the levels of drinking for which these animals were selected. Such findings underscore the need to consider pharmacogenomics when developing new treatments for addiction.
Drug Withdrawal and Relapse
PKA activity is increased during withdrawal from many different addictive drugs. In rats withdrawn from cocaine, PKA activity is increased in the NAc for 30 days, returning to baseline by 90 days after withdrawal. 117 In mice treated chronically with THC, withdrawal precipitated by acute administration of a CB1 antagonist transiently increases PKA activity in the cerebellum and is associated with increased somatic withdrawal signs such as shakes and tremors. 90 In rat striatal neurons, morphine withdrawal precipitated by acute administration of naloxone results in enhanced PKAmediated p-CREB induction. 118 PKA activation and opiate or cannabinoid withdrawal may be causally related. Inhibition of PKA activity decreases withdrawal symptoms in rodents. In THC withdrawn mice, application of Rp-cAMPS to the surface of the cerebellar cortex decreases withdrawal signs. Similar application of Sp-cAMPS in naïve mice mimics some of the signs of THC withdrawal. 90 In rats, injection of Rp-cAMPS into the locus coeruleus or periaqueductal gray matter attenuates signs of morphine withdrawal that are precipitated by naloxone. 91 The role of PKA in ethanol withdrawal is quite different from its roles in cannabinoid or opiate withdrawal. During ethanol withdrawal, CREB phosphorylation is decreased in the rat central and medial amygdala. 115 Local microinjection of Sp-cAMPS into the central amygdala normalizes the level pCREB and attenuates the increased anxiety-like behaviors evoked by ethanol withdrawal. Conversely, microinjection of Rp-cAMPS into the central or basolateral amygdala decreases CREB phosphorylation, increases anxiety, and augments ethanol consumption. The decreased amygdala pCREB is associated with decreased expression of the anxiolytic peptide, neuropeptide Y (NPY). Levels of NPY are increased by local injections of Sp-cAMPS. 119 Intracerebroventricular infusion of NPY decreases the anxiety induced by ethanol withdrawal in rats. 120 In P rats subjected to repeated bouts of ethanol withdrawal, intracerebroventricular infusion of NPY decreases ethanol drinking. 121 In addition to NPY, the neurotrophin BDNF (another CREB-regulated protein) reduces anxiety and drinking behavior. Infusion of BDNF antisense oligonucleotides into the central and medial amygdala, but not into the basolateral amygdala, provokes anxiety-like behavior and increases alcohol intake. Both behaviors are rescued by co-infusion of BDNF. 122 PKA can modulate reinstatement of drugseeking behavior in cocaine-withdrawn rats. Injection of Rp-cAMPS into the NAc of cocaine-withdrawn rats increases responding on cocaine-associated levers. 110 In addition, intraperitoneal priming doses of the D2 agonists 7-OH-DPAT or quinpirole, which can decrease PKA activity via Gα i/o , increase responding on cocaine-associated levers in cocaine-withdrawn rats. The D1 agonist SKF82958, which activates PKA via Gα s has a minimal effect. 123 Therefore, although decreasing PKA activity increases drug seeking in cocaine-withdrawn animals, pharmacological strategies that increase PKA activity are unlikely to be effective in reducing reinstatement of cocaine selfadministration.
Conditioned Place Preference
PKA is required for establishing CPP for several drugs of abuse. The acquisition of amphetamine CPP is decreased in a dose-dependent manner when the PKA inhibitor Rp-cAMPS is co-administered with amphetamine into the NAc during CPP conditioning sessions. 124 Intracerebroventricular injection of the PKA inhibitor H89 immediately after each CPP conditioning session decreases consolidation of cocaine CPP during training. 125 Similarly, microinjections of Rp-cAMPS into the VTA 126 or of H89 into the hippocampal CA1 region 127 after each conditioning session decrease consolidation of morphine CPP. 126, 127 Administration of H89 into CA1 hippocampus before each training session or just before the preference test does not inhibit morphine CPP in rats. Hippocampal PKA thus regulates consolidation but not acquisition or expression of morphine CPP. 127 However, Rp-cAMPS, administered into the VTA immediately prior to preference tests, blocks the expression of morphine CPP. VTA PKA can thus regulate both consolidation and expression of morphine CPP. 126 These results indicate that PKA acts within specific brain regions that mediate drug reward to help mediate acquisition, consolidation, and expression of drug-induced CPP. Acquisition of amphetamine CPP is also decreased by co-injection of the PKA activator Sp-cAMPS into the NAc during conditioning. PKA activation in the NAc that is unrelated to ongoing DA transmission can also disrupt drug reward learning. 124, 128 Cyclin-Dependent Protein Kinase 5
Cdk5 is a proline-directed kinase that regulates many aspects of neuronal function including neuronal migration, axonal and synaptic development, synaptic plasticity, secretion, and cell adhesion. 129 Cdk5 is strongly expressed throughout the cortex, thalamus, and amygdala, and moderately expressed in the midbrain, VTA, and NAc. 6 Cdk5 is inactive alone and requires dimerization with a partner protein, p35, p39, or p67, for activity. Due to restricted expression of these partner proteins, Cdk5 activity is primarily localized to synapses of mature neurons and growth cones of developing neurons. Cdk5 activity is induced by growth factors, such as nerve growth factor (NGF) 130 and BDNF, 131 which increase p35 transcription via ERK-mediated activation of the transcription factor Egr1. 130 Repeated activation of dopamine receptors by exposure to addictive drugs results in accumulation of the long-half-life transcription factor deltaFosB, a splice variant of FosB that increases the transcription of Cdk5. 132 Induction of hippocampal deltaFosB by electroconvulsive treatments increases expression of hippocampal Cdk5 in rats. 133 Cdk5 activity is primarily measured by assessing the phosphorylation of some of the many specific Cdk5 substrates, which include Ser-551 and Ser-553 of synapsin 1, 134 multiple KSPXK sequences in the C-terminus of neurofilament-H, 135 Thr-75 of DARPP-32, 73 and several serine and threonine residues in the N-and C-termini of histone H1. 136 Cdk5 and PKA produce opposing actions on DARPP-32, an important modulator of dopaminergic signaling. As discussed earlier, PKA phosphorylates DARPP-32 on Thr-34, which renders DARPP-32 active as an inhibitor of PP-1. 71 Dopaminergic signaling increases PKA-mediated phosphorylation of DARPP-32 on Thr-34 and inhibits dephosphorylation by PP-1, amplifying dopamine-mediated PKA phosphorylation of downstream targets. 72 Cdk5 negatively regulates dopaminergic signaling by phosphorylating DARPP-32 on Thr-75. This renders DARPP-32 an inhibitor of PKA and reduces PKA phosphorylation of DARPP-32 at Thr-34. 73 Inhibition of Cdk5 with roscovitine decreases DARPP-32 phosphorylation of Thr-75, increases PKA-mediated whole-cell calcium currents, 73 and potentiates cocainestimulated dopamine accumulation in mouse striatal slices. 137 Cdk5 also can inhibit the ERK pathway through phosphorylation and inhibition of MEK. It may thus function in a negative feedback loop that prevents excessive ERK activity. 138 Cdk5 regulation of microtubules and the actin cytoskeleton may be important for druginduced synaptic plasticity. 139 Rats treated with intraperitoneal (i.p.) injections of cocaine for 4 weeks show increased densities of dendritic spines on NAc medium spiny neurons when compared with control rats. This alteration is inhibited by pretreatment with the Cdk5 inhibitor roscovitine. 140 Thus, targeting Cdk5 signaling may be a valuable approach to attenuating drug-induced changes in synaptic plasticity.
Effect of Addictive Drugs on Cdk5 Signaling
Acute administration of cocaine to mice does not affect Cdk5 activity. It does decrease DARPP-32 phosphorylation at Thr-75 via PKA-mediated activation of PP-2A. 72 Chronic administration of cocaine increases Cdk5 activity, likely through the induction of deltaFosB 141 and increased transcription of Cdk5. 82 Rats treated chronically with cocaine show increased Cdk5 and p35 mRNA in the dorsal striatum and NAc. 82 Rats that have been chronically self-administering cocaine display higher NAc Cdk5 protein levels than control rats. 142 Similarly, rats chronically treated with methamphetamine 143 show increased Cdk5 activity in the ventral striatum. Chronic ethanol exposure also increases Cdk5 immunoreactivity in the rat NAc 144 and enhances Cdk5 activity in frontal cortex and cerebellum. 145 Mice treated chronically with cocaine 82 resemble transgenic mice that overexpress p35. 146 In both cases, the effects of single cocaine injections on the induction of PKA-mediated DARPP-32 phosphorylation at Thr-34 are attenuated. Thus, the effects of acute cocaine are dampened in animals exposed repeatedly to cocaine due to the increased expression and activity of Cdk5. High Cdk5 activity can also attenuate downstream activation of other cocaine-stimulated signal transduction pathways. When treated acutely with cocaine, mice that overexpress p35 show reduced phosphorylation of ERK and CREB as well as smaller increases in levels of c-fos than do control mice. 146 Not all addictive drugs increase Cdk5 activity. Chronic exposure to morphine decreases Cdk5 levels in rat brain. 147 Although the effects of in vivo nicotine have not been investigated, in vitro acute nicotine treatments decrease Cdk5-mediated DARPP-32 phosphorylation in mouse striatal slices. 148 For psychostimulants and ethanol, Cdk5 appears to serve as a negative regulator of excess dopaminergic activity and may provide a mechanism for dopaminergic homeostasis during repeated exposure to these drugs.
Cdk5 in Behavioral Responses
to Drugs of Abuse
Sensitization
Repeated cocaine injections that result in locomotor sensitization increase Cdk5 levels and Cdk5-mediated DARPP-32 phosphorylation, and decrease PKA-mediated DARPP-32 phosphorylation in the rat dorsal striatum and NAc. 149 Pretreatment with the Cdk5 inhibitors roscovitine or olomoucine enhances the development of cocaine-induced locomotor sensitization in mice 82 and rats. 150 In contrast, heterozygous Cdk5 null mice show reduced morphine-induced locomotor sensitization. 151 However, conditional Cdk5 knockout mice, in which forebrain deletion of Cdk5 is achieved in the adult through αCaMKII promoter-driven Cre recombinase, show enhanced cocaine-induced locomotor sensitization. 152 Therefore, induction of Cdk5 activity by repeated exposure to cocaine appears to act as an adaptive feedback response that decreases the sensitizing effects of the drug, whereas for morphine Cdk5 appears to facilitate drug sensitization. The mechanisms by which Cdk5 regulates sensitization are not understood but may involve both its kinase activity as well as its recently described kinase independent role in regulating glutamate receptor degradation. 153 
Drug Tolerance
Cdk5 may also regulate the development of tolerance to morphine analgesia. Intrathecal injection of roscovitine prevents the development of tolerance and reverses established tolerance to morphine analgesia. 154 Interestingly, this result is similar to the effect of PKA inhibition on morphine tolerance, 108, 109 indicating that here Cdk5 and PKA show similar, rather than antagonistic, actions.
Motivated Responding for Cocaine
Repeated exposure to cocaine increases Cdk5 levels, and this appears to exert negative feedback on motivated responding for the drug. 82 In rats, intra-NAc injections of the Cdk5 inhibitor olomoucine increase the work which an animal is willing to expend to obtain an injection of cocaine in a progressive ratio paradigm. 150 The Cdk5 inhibitor roscovitine, injected into the NAc increases conditioned reinforcement induced by cocaine, which can also be considered a measure of incentive motivation. 150 
Drug Withdrawal
Cocaine self-administration for 10 days followed by withdrawal for 1, 30, or 90 days does not alter Cdk5 levels in the rat NAc, but withdrawal for 1 day does increase Cdk5 protein in the rat VTA. 117 Cdk5 does not increase in the VTA of sucrose-withdrawn rats. The effect of withdrawal from other drugs on Cdk5 levels and the effect, if any, of increased Cdk5 in the VTA on behavioral signs of cocaine withdrawal are not known.
Conditioned Place Preference
Intracerebroventricular injections of roscovitine reduce the development of morphine CPP in mice, and heterozygous Cdk5 knockout mice show attenuated development of morphine CPP compared with wild-type controls. 151 However, similar to the effects of Cdk5 on locomotor sensitization discussed above, a different result has been observed for cocaine. In conditional Cdk5 knockout mice, cocaine can cause CPP at low doses that do not induce CPP in wild-type mice, suggesting that decreasing Cdk5 activity reduces the threshold for the development of cocaine CPP. 152 The findings in conditional knockout mice suggest that Cdk5 reduces cocaine reward and fits well with results from cocaine selfadministration studies noted above, in which Cdk5 acts to decrease motivated responding for cocaine.
Protein Kinase C
Protein kinase C (PKC) is a family of serinethreonine kinases comprising nine genes, all of which are expressed in the central nervous system with isozyme-specific patterns of expression. 155 PKC isozymes can be classified into three subgroups based on similarities in structure and regulation: the conventional PKCs (cPKC, α, β, and γ), the novel PKCs (nPKC, δ, ε, η, and θ), and the atypical PKCs (aPKC, ζ, and ι/λ). 156 Conventional PKCs are activated by diacylglycerol (DAG) and calcium, novel PKCs are activated by DAG but not calcium, and the atypical PKCs are not activated by DAG or calcium but instead by other lipid second messengers, such as arachidonic and phosphatidic acid. 157 The hydrolysis of phosphatidylinositol-4,5-bisphosphate by phospholipase C (PLC) generates inositol triphosphosphate (IP3) and DAG. IP3 releases intracellular calcium stores to increase intracellular calcium levels, which can synergize with DAG to activate conventional PKCs.
PKCs are involved in many cellular processes, and thus the downstream substrates of PKCs are numerous. They include several neurotransmitter receptors such as the α4 nACh receptor which can be PKC phosphorylated on Ser-550; 158 159 and CB1 receptors phosphorylated by PKC at Ser-317. 160 Other PKC substrates include proteins involved in exocytosis (including Ser-187 of SNAP-25) 161 as well as proteins important in synaptic plasticity (such as Ser-36 of neurogranin 162 and Ser-41 of neuromodulin). 163 In addition, PKC phosphorylates Ser-818 of GluR1, facilitating AMPA receptor externalization and LTP. 164 Thus, PKCs may play an important role in drug-induced synaptic plasticity.
Addictive drugs can activate PKCs by stimulating dopamine D2, opioid, or cannabinoid receptors, releasing Gβγ from G i/o , which stimulates PLC to produce DAG and IP3. 165 In addition, hetero-oligomers of D1 and D2 dopamine receptors activate G q , 166 which also activates PLC. 165 Phospholipase D (PLD) can produce DAG by cleaving phosphatidylcholine into phosphatidic acid (PA) and free choline. 167 PA is then converted to DAG by PA phosphohydrolase. PLD is also activated by many of the same G protein-coupled receptors as PLC, as well as by the small GTPase RhoA and by cPKCs. 167 PKCs require phosphorylation by phosphoinositide-dependent kinase 1 (PDK1) and subsequent autophosphorylation in the catalytic domain to be fully active. For conventional PKCs, this is thought to be a constitutive process, whereas for novel and atypical PKCs, there is a pool of unprocessed enzyme present that can be phosphorylated by PDK1 and recruited into an activatable pool. 156 Activation of PKC isozymes involves their translocation to specific subcellular compartments where they can interact with substrates. This process is regulated by binding proteins, such as the protein interacting with C kinase 1 (PICK1), 168 which localizes PKC at AMPA receptors, and by the Receptors for Activated C Kinase (RACKs), two of which have been cloned: RACK1 which binds activated PKCβII 169 and εRACK (β COP) which binds activated PKCε. 170 The function of PKC isozymes can be probed using activators such as tumorpromoting phorbol esters, which activate conventional and novel PKCs, although it is important to note that other proteins besides PKCs can be activated by phorbol esters. 171 However, when reversed by inhibitors of PKC catalytic activity, it is possible to ascribe effects of phorbol esters to activation of PKC. The activation of PKCs can be measured as autophosphorylation of PKCs or their translocation to different cellular compartments. Several inhibitors are commonly used, such as bisindolylmaleimides and related compounds that bind to the purine site in the catalytic domain, or other compounds that do not compete with ATP binding such as chelerythrine and calphostin C. It is important to note that these inhibitors do not distinguish well between PKC isozymes, although one, the indolocarbazole Gö6976, inhibits conventional PKCs with good selectivity over novel and atypical PKCs. 172 Isozymespecific manipulations have been best achieved through the use of isozyme-selective peptide inhibitors derived from putative RACK binding domains, over-expression of isozymes, expression of dominant negative mutants of specific isozymes, gene targeting or expression of PKC transgenes, antisense RNA, or RNA interference.
Effects of Addictive Drugs on PKC Signaling
Treatment with phorbol esters increases striatal extracellular dopamine levels in rat brain slices, 173 and amphetamine-stimulated dopamine accumulation in rat striatal slices is inhibited by the PKC inhibitors chelerythrine, calphostin C, and Ro31-8220. 173, 174 Nicotinic agonists cause translocation of PKC activity to the particulate fraction of PC12 cells, a rat neuroendocrine cell line. 175 In PC12 cells, nicotine also acutely stimulates dopamine release, which is inhibited by chelerythrine. 176 Therefore in some in vitro models PKC modulates levels of extracellular dopamine.
Chronic stimulant treatment has differential effects on the levels of individual PKC isozymes. Chronic treatment of PC12 cells with 1.0 μM of cocaine increases levels of PKCα and PKCδ and decreases levels of PKCε and PKCγ. 177 Chronic cocaine treatment in rats increases PKCβI in the medial prefrontal cortex, 178 PKCα and PKCε in the hippocampus, 179 and PKCγ in the amygdala and NAc core but decreases PKCγ in rat striatum. 178 Chronic methamphetamine treatment increases levels of phosphorylated conventional PKC isozymes in rat limbic forebrain 180 and levels of phosphorylated PKCs in astrocytes. 181 PKC mediates several effects of chronic psychostimulant exposure. Chronic treatment with nicotine enhances amphetamine-induced dopamine accumulation in slices of rat prefrontal cortex, and this effect is attenuated by chelerythrine. 182 In rat NAc, methamphetamine-induced sensitization of extracellular dopamine accumulation is attenuated by intra-NAc injections of chelerythrine. 180 Chronic cocaine treatment results in impairment of type 1 mGluR-mediated induction of long-term depression (LTD) in pyramidal neurons of the rat medial prefrontal cortex, an effect that is attenuated by pretreatment with bisindolylmaleimide I (BIS). 183 The role of PKC in chronic effects of opioid or cannabinoid agonists has not been studied. One report 184 has shown that chronic morphine treatment increases and decreases specific PKC isoforms in mouse brain, similar to psychostimulant treatment. In mice, repeated morphine injections increase PKCγ protein levels in the limbic forebrain but not in the lower midbrain. There is no effect of chronic morphine treatment on PKCα, PKCβI, PKCβII, or PKCε in either brain region.
Interactions between ethanol and PKC have been more extensively investigated than PKC interactions with other addictive drugs. Similar to stimulants and opioids, ethanol alters the localization and abundance of PKC. Acute ethanol treatment induces PKC translocation in cultured astroglial cells. 185 In the neuroblastoma × glioma hybrid cell line NG108-15, chronic ethanol exposure also induces translocation of PKCδ and PKCε; 186 this translocation of PKCε is to the cytosol in a complex with εRACK and is mediated by PKA, possibly through PKA phosphorylation of εRACK. 187 In vivo ethanol administered i.p. stimulates phosphorylation of cerebellar PKCε at Ser-729, and this increase in phosphorylated PKCε correlates with the development of acute functional tolerance to the motor-impairing effects of ethanol in mice that is PKCε-dependent. 188 Chronic ethanol exposure increases PKC activity and PKCδ and PKCε protein levels in PC12 cells and in NG-108-15 cells. 189 In vivo, chronic ethanol treatment decreases PKC activity in the cortex and hippocampus of rats, 190 decreases PKCα and PKCγ levels in the frontal cortex in mice, 191 and increases PKCα and PKCγ protein levels in the limbic forebrain in mice. 191 In vitro studies with peptide inhibitors have been informative in elucidating the role of PKC isozymes in mediating effects of ethanol. Chronic exposure of PC12 cells to ethanol upregulates the abundance of N-type calcium channels, an effect that is blocked by a peptide inhibitor of PKCε. 192 Chronic ethanol treatment also enhances NGF-induced neurite outgrowth in PC12 cells, and this response is also attenuated by depletion 193 or inhibition of PKCε. 194 In PC12 cells, chronic ethanol exposure causes an upregulation of L-type calcium channels, which is mediated by PKCδ. 195 Knockout mice and isozyme-selective peptide inhibitors have been also useful in identifying roles for PKC isozymes in effects of ethanol in vivo. Thus, ethanol-induced dopamine release in the NAc appears to require PKCε as it is attenuated in PKCε knockout mice. 196 Acute ethanol treatment increases glycine currents in rat VTA neurons; a peptide inhibitor of PKCε reduces this effect. 197 Acute ethanol exposure also potentiates GABA A receptor-mediated inhibitory postsynaptic currents in hippocampal pyramidal cells, an effect that is increased in neurons from PKCε knockout mice and abolished in neurons from PKCγ knockout mice. 198 PKCγ can be co-immunoprecipitated with α1 and α4 GABA A receptor subunits, 199 suggesting that PKCγ interacts directly with GABA A receptors to mediate its effect on receptor function. The PKCγ substrates that mediate this response are not known. On the other hand, PKCε regulates GABA A receptor function by phosphorylating γ2 subunits of synaptic receptors at Ser-327, which results in a diminished enhancement of GABA-stimulated current by ethanol. 200 Initial activation of nACh receptors by agonists results in a downregulation and desensitization of the receptor, followed by receptor inactivation and a paradoxical upregulation with chronic agonist exposure. 201 Postmortem studies show that smokers have increased nicotinic receptor binding in the brain compared with nonsmokers. 202 This nACh receptor upregulation may contribute to the reinforcing effects of nicotine. 203 PKC appears to play an important role in nACh receptor cycling. The high-affinity α4β2 nACh receptor is upregulated by chronic nicotine treatment in rats, 204 and receptors containing the β2 subunit are implicated in the reinforcing properties of nicotine as mice lacking the β2 subunit show attenuated nicotine self-administration. 205 Acute nicotine treatment desensitizes α4β2 nACh receptors, which can recover from desensitization if nicotine treatment is stopped. 206 Inhibition of PKC with calphostin C slows recovery, whereas activation of PKC with phorbol esters enhances it. 206 In addition, the α4 nicotinic subunit contains a PKC phosphorylation site at Ser-366, and mutation of this site produces receptors that show little recovery from desensitization. 206 Interestingly, ethanol can also downregulate nACh receptors, an effect that is attenuated by chelerythrine. 207 Chronic nicotine treatment inactivates α4β2 nACh receptors, and this inactivation is mimicked by the PKC inhibitor 2,6-diamino-N-([1-(1oxotridecyl)-2-piperidinyl] methyl)hexanamide (NPC 15437). 208 Prolonged nicotine treatment upregulates homomeric α7 nACh receptors expressed in SH-EP1-hα7 cells, and this upregulation is enhanced by PKCα over-expression; however, upregulation of heteromeric nACh receptors containing α3, α5, α7, β2, and β4 expressed in SH-SY5Y cells is not affected by depletion of PKC. 209 These data suggest that PKC is important for recovery from receptor desensitization, receptor inhibition resulting from chronic agonist treatment, and upregulation of homomeric α7 NACh receptors resulting from chronic agonist treatment. Which PKC isozymes mediate these processes is not yet known.
PKC in Behavioral Responses
to Drugs of Abuse Sensitization PKC inhibition attenuates psychostimulantinduced hyperlocomotion. Intra-NAc infusion of the PKC inhibitor Ro31-8220 inhibits hyperlocomotion induced by amphetamine in rats. 174 In cocaine-sensitized rats, cocaineinduced hyperlocomotion is also attenuated by intra-NAc injection of the PKC inhibitor BIS. 174 Co-administration of the PKC inhibitor NPC 15437 with repeated injections of methamphetamine attenuates the development of locomotor sensitization in mice. 181 
Drug Tolerance
Similar to PKA and Cdk5, PKC appears to play a role in opioid tolerance. Intracerebroventricular injection of the PKC inhibitor BIS restores analgesic sensitivity in mice tolerant to morphine analgesia. 109 However, unlike inhibition of PKA, inhibition of PKC does not restore analgesic sensitivity to THC in mice made tolerant to THC. 107 PKC knockout mice have been useful in determining the role of PKC isozymes in ethanol-related behaviors. Administration of high concentrations of ethanol (3.2-4 g/kg) produces hypnosis and anesthesia, which can be measured as the loss of righting reflex (LORR) in rodents. PKCε knockout mice show an increased duration of the ethanol-induced LORR 210 that is due to decreased acute functional tolerance to ethanol. 188 PKCε knockout mice also show increased duration of LORR induced by pentobarbital, pregnanolone, or benzodiazepines. [210] [211] [212] Restoration of PKCε activity by conditional gene expression of PKCε in knockout mice reduces ethanol-and pentobarbital-induced LORR to wild-type levels. 211 In contrast to PKCε knockout mice, PKCγ knockout mice show a reduced duration of ethanol-induced LORR compared with wild-type mice. 213 Unlike with PKCε knockout mice, this change in LORR duration appears specific for ethanol since PKCγ knockout mice show no differences in pentobarbital-induced LORR. 213 PKCγ knockout mice also do not develop tolerance to ethanol-induced LORR or hypothermia on some genetic backgrounds. 214 PKCε and PKCγ knockout mice show differences in anxiety-like behavior compared with wild-type mice. PKCε knockout mice have decreased anxiety-like behavior and lower levels of stress hormones compared with wild-type mice, which may be due to increased sensitivity of their GABA A receptors to modulation by endogenous neurosteroids. 212 PKCγ knockout mice also show decreased anxietylike behavior compared with wild-type mice 215 and are less sensitive to the anxiolytic effects of ethanol. 216 However, PKCγ knockout mice show no differences in flunitrazepam-induced anxiolysis compared with wild-type mice, 216 suggesting that the effect of PKCγ is specific to ethanol and not a general effect on other GABA modulators, as seen with the PKCε knockout mice. PKCγ knockout mice also show greater impulsivity than wild-type mice. 217 Interestingly, genetic polymorphisms in PKCγ were recently associated with behavioral disinhibition, attention-deficit/hyperactivity disorder, and substance experimentation in one human genetic study. 218
Drug Self-Administration and Withdrawal
PKCε and PKCγ knockout mice show opposite responses in ethanol self-administration paradigms. PKCε knockout mice selfadminister less ethanol 196, 210 and have decreased preference for ethanol compared with wild-type mice. 210 PKCε activity is decreased by mGluR5 antagonists, 219 and systemic administration of the mGluR5 antagonist MPEP decreases ethanol consumption in wild-type mice but not in PKCε knockout mice. 220 Restoration of neuronal PKCε activity by conditional gene expression of PKCε in knockout mice increases ethanol consumption to wild-type levels indicating that the effect of the PKCε null mutation on drinking is not due to a developmental abnormality but results instead from deficient PKCε signaling in the adult nervous system. 211 In contrast to PKCε knockout mice, PKCγ knockout mice consume more ethanol than wild-type littermates. 217 Studies with PKCε knockout mice indicate that PKCε regulates sensitivity to opiates. PKCε knockout mice develop self-administration of morphine at a lower dose and show a greater analgesic response to morphine than wild-type mice. 221 It is not known whether the magnitude of self-administration is different at higher doses. Therefore, PKCε reduces acute sensitivity to opiates, but it is not yet known if PKCε alters the reinforcing properties of opiate drugs.
Alcohol withdrawal results in handlinginduced convulsions in mice. 222 PKCε knockout mice show reduced severity of handlinginduced convulsions during abstinence from chronic ethanol exposure. 223 In addition, chronic ethanol exposure, particularly when administered in a binge fashion interspersed with periods of abstinence, produces a hyperalgesia in rats that can be attenuated by decreasing PKCε activity through local injection of a PKCε inhibitor peptide into the paw being tested 224 or by intrathecal administration of antisense oligonucleotides against PKCε. 225 These findings indicate that PKCε contributes to some of the peripheral and central nervous system manifestations of ethanol withdrawal.
Conditioned Place Preference
Nonselective PKC inhibitors decrease CPP induced by many addictive drugs. In rats, chelerytrhine reduces cocaine-induced CPP when administered by intracerebroventricular injection 125 and inhibits methamphetamineinduced CPP when administered through intra-NAc injection. 180 Likewise, intra-NAc injection of NPC 15437 reduces amphetamineinduced CPP. 226 It is not known which PKC isozymes regulate psychostimulant-induced CPP. Studies with PKCγ and PKCε knockout mice have revealed different roles for these isozymes in regulating morphine-induced CPP. Morphine CPP is abolished in PKCγ knockout mice, 184 whereas PKCε knockout mice show CPP at low doses of morphine and more prolonged expression of morphine CPP when compared with wild-type mice. 221 In contrast to morphine, low doses of ethanol do not result in CPP in PKCε knockout mice but instead cause conditioned place aversion. 227 Aversion to low doses of ethanol may explain, in part, why PKCε knockout mice self-administer less ethanol than wild-type littermates. Ethanol CPP has not yet been investigated in PKCγ knockout mice.
Calcium/Calmodulin-Dependent Protein Kinase II
The CaMKII family consists of four closely related genes that encode for α, β, γ, and δ isoforms, which associate as homomers or heteromers to form holoenzymes comprised of 12 functional units. 228 CaMKIIα is expressed heavily in the cortex and amygdala, moderately in the NAc, and very moderately in the VTA and midbrain. 6 CaMKII is involved in many aspects of neuronal function including synaptic plasticity, gene expression, and neurotransmitter synthesis and release. 229 Each functional holoenzyme subunit contains a catalytic and a regulatory domain; the regulatory domain includes an auto-inhibition sequence, a calmodulin binding site, and sites for autophosphorylation. 228 CaMKIIs are activated by the binding of calcium to calmodulin (which acts as a calcium sensor), resulting in release of auto-inhibition allowing for autophosphorylation within the regulatory domain.
Autophosphorylation on Thr-286 disables the auto-inhibitory domain, increases the affinity for Ca 2+ /calmodulin by 1000-fold, and allows the holoenzyme to bind to NMDA receptors. 228 The CaMKII holoenzyme is activated to differing degrees depending on the magnitude and duration of the intracellular calcium signal, and autophosphorylation allows for increases in CaMKII activity to persist for hours after levels of intracellular calcium fall. 230 Activation of CaMKIIs often involves translocation to target areas and binding to target proteins. Thus, activation of CaMKII can be measured by translocation, or more often by an increase in autophosphorylation or phosphorylation of a specific substrate. CaMKII phosphorylates many substrates important in neuronal function and for responses to addictive drugs including synapsin I at Ser-603, 231 CREB at Ser 133 and Ser-142, 232 and the AMPA GluR1 subunit at Ser-831. 233 Activated CaMKII can also bind to the NR2B subunit of NMDA receptors and contribute to synaptic plasticity and LTP. 234 Mutation of the αCaMKII autophosphorylation site Thr-286 abolishes stimulus-evoked LTP in rat hippocampal slices and results in spatial memory deficits in the mutant mice. 234 In rat hippocampal cultures, the dopamine D1 agonist SKF 81297 increases GluR1 trafficking to the cell surface, which is partially attenuated by the CaMKII inhibitor KN-62. 79 Thus CaMKII plays an important role in synaptic plasticity.
Effects of Addictive Drugs on CaMKII Signaling
Acute administration of psychostimulants has variable effects on CaMKII activity depending on the particular stimulant drug and brain region examined. In rats, acute cocaine treatment (15 mg/kg i.p.) increases CaMKII activity in the NAc, 235 whereas acute amphetamine treatment (5 mg/kg i.p.) increases CaMKII activity in the striatum 236 and produces several downstream CaMKIIdependent events. Inhibition of CaMKII activity with KN93 attenuates acute amphetamineinduced dopamine efflux from mouse striatal neurons, brain slices, and, in vivo, from the dorsal striatum. 237 In mouse striatal synaptosomes, acute amphetamine administration decreases dopamine transporter expression at the cell surface, and this effect is attenuated by KN93. 238 In contrast to these effects of amphetamine, acute treatment with methamphetamine (5 mg/kg i.p.) decreases CaMKII activity in the rat striatum, parietal cortex, NAc, frontal cortex, and hippocampus. 239 There is cross-talk between CaMKII, ERK, and PKA pathways, with CaMKII modulating stimulant-induced activation of ERK and PKA. In vitro, CaMKII inhibitors attenuate acute nicotine-induced ERK phosphorylation in mouse striatal neurons. 37 In rat striatal neurons, acute treatment with a dopamine D1 receptor agonist 75 and an NMDA agonist 240 increases levels of p-CREB, which is attenuated by the CaMKII inhibitor KN62. In vivo in rats, intrastriatal infusion of the CaMKII inhibitor KN62 dose-dependently inhibits increases in p-ERK and p-CREB induced by acute administration of amphetamine. 236 Chronic exposure to psychostimulants increases CaMKII activity when given continuously, intermittently, or by self-administration. In rats, chronic amphetamine treatment increases striatal CaMKII activity but not protein levels 241 and chronic intermittent amphetamine treatment increases striatal CaMKIIβ mRNA. 242 Chronic cocaine treatment in mice increases CaMKII protein in the VTA, 243 and chronic cocaine selfadministration in rats increases CaMKII mRNA in the VTA. 244 In rats treated for 1 week with daily cocaine injections, the enhanced dopamine accumulation in the NAc resulting from acute amphetamine administration is blocked by intra-NAc injections of the CaMKII inhibitor KN93. 245 The effect of chronic nicotine on CaMKII activity has not yet been investigated in animal studies or in vitro. In one negative postmortem study, brains from smokers and nonsmokers had similar levels of CaMKII in the ventral midbrain. 86 CaMKII is modulated by cannabinoids and opiates. Acute treatment with low doses of THC in rats decreases CaMKII activity in the hippocampus, 246 whereas high doses of morphine acutely increase levels of phosphorylated CaMKII in whole mouse brain homogenates. 247 Chronic treatment with morphine increases levels of CaMKIIα in rat hippocampal synaptosomes. 248 Withdrawal from chronic drug treatment has differential effects on CaMKII activity. In rats, methamphetamine withdrawal does not alter CaMKII activity in the parietal cortex, NAc, or striatum, but a subsequent challenge dose of methamphetamine reduces CaMKII activity in these brain regions to a greater degree in methamphetamine-withdrawn rats compared with drug-naïve rats. 239 Naloxone-precipitated morphine withdrawal increases autophosphorylation of CaMKIIα and CaMKIIβ in mouse cingulate cortex. 249 Precipitated and unprecipitated withdrawal increase CaMKII activity and CaMKIIβ protein and mRNA, but not CaMKIIα protein or mRNA, in the rat hippocampus. 250 Instead unprecipitated morphine withdrawal decreases autophosphorylated CaMKIIα in synaptosomal fractions of rat hippocampus. 248 CaMKII activity plays a role in μ-opioid receptor desensitization, 251 which may be important for the development of opioid tolerance. CaMKII phosphorylates the μ-opioid receptor on Ser-261 and Ser-266 in the third intracellular loop, and phosphorylation at these sites mediates receptor desensitization, since mutation of these phosphorylation sites results in a receptor that does not show desensitization to repeated agonist administration. 252 
CaMKII in Behavioral Responses
to Drugs of Abuse Sensitization CaMKII contributes to drug-induced hyperlocomotion and locomotor sensitization. In rats, repeated intra-VTA treatment with the glutamate receptor agonist t-ACPD enhances cocaine-induced hyperlocomotion, and this effect is attenuated by intra-VTA injection of KN93. 253 In rats, repeated cocaine administration induces locomotor sensitization, which is inhibited by intra-VTA injection of KN93 243 and partially attenuated by intra-NAc injection of KN93. 254 CaMKII knockout mice develop cocaine-induced locomotor sensitization, but the magnitude of the sensitization is significantly less than in wild-type mice. 243 
Drug Tolerance
In rats, the development of tolerance to morphine analgesia is attenuated by intrahippocampal injections of the CaMKII inhibitors KN62 and KN93, or CaMKII antisense oligonucleotides. 255 This is similar to the attenuation of tolerance to morphine analgesia by PKA inhibition with intracerebroventircular injection of PKA antisense oligonucleotides 108 or of Cdk5 inhibition by intrathecal injection of roscovitine. 154 These parallel results indicate that tolerance to morphine analgesia is mediated by several protein kinases and all are necessary for its expression.
Drug Withdrawal
The effect of CaMKII inhibition on drug withdrawal has not been extensively studied. However, some evidence indicates that CaMKII contributes to opioid dependence and withdrawal. In rats treated chronically with morphine, signs of naloxone-precipitated withdrawal are decreased by intrahippocampal injections of KN62 or KN93 255, 256 or by CaMKII antisense oligonucleotides. 255 
Conditioned Place Preference
CaMKII activity in the hippocampus is important for expression of drug-induced CPP. Repeated injections of amphetamine during CPP conditioning increase CaMKII activity in the rat hippocampus. 257, 258 Expression of amphetamine CPP is attenuated by pretreatment with intrahippocampal injections of KN93 during conditioning 257, 258 or immediately before the CPP test. 257 However, intra-NAc injections of KN93 during the conditioning phase have no effect. 258 Expression of morphine CPP in rats is also attenuated by intrahippocampal injections of KN62 or KN93 during conditioning 255, 256 and immediately before the CPP test. 256 
Fyn
Fyn is a member of the Src family of nonreceptor tyrosine kinases 259 and is expressed throughout the brain, with moderate expression in the amygdala, NAc, VTA, and midbrain. 6 Fyn is composed of six domains: an Src homology region that contains lipid modification sites, a unique region, SH2 and SH3 domains, a catalytic domain, and a short autoinhibitory tail. Fyn is constitutively inactive, a state that is maintained by blockade of the catalytic region by the SH2 and SH3 domains and the auto-inhibitory tail. Phosphorylation at Tyr-527 maintains the interaction of the SH2 region with the catalytic domain. Activation of Fyn involves dephosphorylation of Tyr-527 and release of the SH2 and SH3 domains and autoinhibitory tail from the catalytic domain, as well as autophosphorylation at Tyr-416. 259 Fyn activation is commonly measured as an increase in autophosphorylation at Tyr-416.
Fyn plays an important role in synaptic plasticity and LTP. Knockout of the fyn gene, and not other members of Src kinase family, results in abnormal hippocampal development, deficient hippocampal LTP, and impaired spatial learning. 260 Reintroduction of Fyn into knockout mice rescues hippocampal development and induction of LTP. 260 Fyn interacts with and regulates the function of many neurotransmitter receptors in the brain and mediates effects of neurotrophins. 261 For example, Fyn colocalizes with and mediates adenosine-induced transactivation of Trk-A and Trk-B neurotrophin receptors in vitro. 262 Fyn also interacts directly with 5-HT 6 receptors through its SH3 domain, and this interaction increases Fyn activity via an unknown mechanism. 263 In addition, serotonin-dependent activation of ERK is mediated by Fyn, 263 indicating cross-talk between Fyn and ERK signal transduction pathways. Fyn directly interacts with the α7 nACh receptor and may contribute to neuroprotection induced by nicotinic receptor stimulation. 264 In addition, Fyn can increase NMDA receptor activity by phosphorylating the NR2B subunit of NMDA receptors, which may modulate susceptibility to seizures 265 and underlie BDNF-induced increases in NMDA receptor function. 266 
Effects of Ethanol on Fyn Signaling
Acute ethanol treatment increases Fyn activity in the rat dorsal striatum, 267 cerebral cortex, and cerebellum. 268 Ethanol also acutely and transiently inhibits NMDA receptor-mediated excitatory postsynaptic potentials (EPSPs) in the hippocampus, which eventually return to baseline, indicating that NMDA receptors develop an acute tolerance to the inhibitory effects of ethanol. 269 Fyn is critical for this process since Fyn knockout mice do not show acute tolerance to ethanol. 269 Fyn and NMDA NR2B are found in a complex with the scaffolding protein RACK1, 267, 270, 271 and RACK1 inhibits phosphorylation of NR2B by Fyn. 270 Ethanol increases NMDA NR2B subunit phosphorylation 267, 269 by dissociating this complex, enabling Fyn to phosphorylate NR2B and increase NMDA receptor function. 271 Overexpression of RACK1 prevents phosphorylation of NR2B by Fyn and prevents the development of tolerance to the inhibitory effects of ethanol on NMDA receptor function in vitro. 271 Thus, ethanol itself normalizes NMDA function by stimulating RACK1 dissociation from the complex, thereby enabling Fyn to phosphorylate NR2B and increase NMDA receptor function.
Fyn in Behavioral Responses to Ethanol
Ethanol Intoxication and Acute Tolerance
Fyn knockout mice and mice that overexpress Fyn under control of an αCaMKII promoter in the forebrain, amygdala, and hippocampus (OVF mice) have been used to investigate the role of Fyn in behavioral responses to ethanol. Homozygous Fyn knockout mice show an increase, 272, 273 and OVF mice show a decrease, in the duration of the ethanolinduced LORR 274 when compared with their corresponding wild-type littermates. Homozygous Fyn knockout mice also show an increase in the duration of ethanol-induced LORR when compared with heterozygous Fyn knockout mice 269 or wild-type littermates. 272 Neither Fyn knockout mice 272, 273 nor OVF mice 274 show differences in ethanol clearance or initial sensitivity to ethanol. Fyn modulation of NMDA receptor activity may contribute to differences in acute sensitivity to the hypnotic effects of ethanol, since pretreatment with the NR2B-containing NMDA receptor antagonist ifendopril increases the duration of ethanolinduced LORR in wild-type mice to levels seen in homozygous Fyn knockout mice. 272 Fyn knockout mice show decreased acute functional tolerance to ethanol, which contributes to their enhanced response to hypnotic doses of ethanol. 273 They also show a greater anxiolytic effect of ethanol compared with wildtype mice on the elevated plus-maze, possibly due to an increased basal level of anxiety-like behavior. 273
Ethanol Self-Administration
Deletion of Fyn does not appear to affect ethanol self-administration in mice. Female Fyn knockout mice show no differences in ethanol self-administration compared with wild-type mice. 273 Depending on the laboratory, male Fyn knockout mice show decreased 273 or no difference in ethanol preference compared with wild-type mice. 272, 275 Male Fyn knockout mice also show no change in stress-associated ethanol self-administration 275 or ethanol CPP compared with wild-type mice. 272 However, micro-injection of the Fyn kinase inhibitor PP2 or the NR2B inhibitor ifendopril into the dorsal striatum reduces ethanol self-administration in wild type animals, suggesting that the absence of phenotypes in the Fyn knockout may be due to compensatory changes in other gene products that mask a role for Fyn in regulating ethanol self-administration and reward. 267 In contrast to Fyn knockout mice, OVF mice show decreased ethanol consumption and preference. 274, 276 Ethanol Withdrawal and Anxiety OVF mice do not differ from wild-type mice in anxiety-like behavior as measured by the light-dark test. 276 However, when withdrawn from chronic alcohol consumption, wild-type mice show increased anxiety-like behavior, while OVF mice do not. NR2B is hyperphosphorylated in OVF mice, and treatment with the NR2B antagonist ifendopril in alcohol-withdrawn OVF mice increases anxiety-like behavior to levels observed in alcohol-withdrawn wild-type mice. In contrast ifendopril only slightly decreases anxiety-like behavior in alcohol-withdrawn wild-type mice. This suggests that increased phosphorylation of NR2B in OVF mice prevents increases in anxiety-like behavior induced by alcohol withdrawal.
Human Fyn Variants and Alcohol Use Disorders
In one human genetic study, a T-to-C change at genomic position 137346 (−93A/G) in the 5 untranslated region of the fyn gene is associated with increased alcohol consumption, a higher number of drinks consumed, and a greater number of self-reported alcohol withdrawal symptoms as defined by DSM-IV criteria compared with control subjects. 277 The functional consequences of this polymorphism are not known, but it is likely to affect expression of Fyn.
Cross-Talk in Protein Kinase
Signaling Pathways
The individual signaling cascades that activate ERK, PKA, PKC, CaMKII, and Fyn often affect each other, resulting in cross-talk that can influence the activity or downstream effects of other kinases. These interactions can have similar or opposing effects on downstream targets. PKA and ERK signaling pathways converge, resulting in phosphorylation of the same serine residue on CREB. PKA can also indirectly activate ERK by activating the small G-protein Rap1, which then activates B-Raf, leading to activation of MEK and ERK (Fig. 1 ). 60 Thus, PKA cross-talk with ERK can amplify CREB-mediated gene transcription. CaMKII indirectly modulates the stimulantinduced activation of PKA and ERK signaling pathways. CaMKII inhibitors decrease the activation of ERK by nicotine, 37 decrease the activation of ERK and CREB by amphetamine, 236 and decrease D1 75 and NMDA agonist induction of CREB. 240 Thus, the inhibition of CaMKII activity may have negative effects on the downstream targets of PKA and ERK pathways.
Cdk5 inhibits PKA and ERK signaling pathways in a negative feedback manner. PKA and Cdk5 act on the same downstream target, DARPP-32, resulting in opposing effects on dopaminergic signaling. Dopamine acutely activates PKA phosphorylation of DARPP-32, 72 which enhances dopaminergic signaling. 71 Repeated stimulation of dopamine receptors activates Cdk5 phosphorylation of DARPP-32, 132 which inhibits dopaminergic signaling. 73 Thus, the balance between PKA and Cdk5 activity and phosphorylation of DARPP-32 determines the overall level of dopaminergic signaling. NGF 130 and BDNF 131 activate ERK, which increases p35 transcription and Cdk5 activity. 130 Cdk5 inhibits MEK and ERK activity and may act to limit excessive activation of ERK. 138 PKA and ERK signaling pathways show cross-talk with PKC and Fyn pathways, respectively, allowing for integration of different effector signals. PKC can be activated by lipid second messengers generated through receptors coupled to phospholipase C and can in turn activate certain adenylyl cyclases (AC2, AC4, and AC7), leading to activation of PKA. 66 Since PKA is primarily activated by receptors coupled to AC via Gα s , this PKC-AC interaction allows for integration of intracellular signals arising from PLC-and AC-coupled receptors. Fyn kinase interacts with the 5-HT 6 receptor and mediates the serotonin-dependent activation of ERK, 263 allowing integration of serotonin signaling with calcium and neurotrophin stimulation of ERK.
These examples of cross-talk between signaling pathways demonstrate the complex interactions between pathways. Drug-induced activation of protein kinase pathways may have numerous effects on other second messengers, culminating in complex modulation of gene transcription and protein synthesis in drug addiction. Cross-talk between signaling pathways increases the difficulty in predicting the result of targeting a particular protein kinase for drug development, as it may effect multiple signaling pathways.
Summary and Drug-Target Development
Addictive drugs primarily alter the function of receptor-gated ion channels (nicotine, alcohol), neurotransmitter transporters (cocaine, amphetamine) or G protein-coupled receptors (opiates, cannabinoids), and these initial events lead to activation of signaling pathways that result in the activation of the downstream protein kinases described in this review. With the exception of alcohol, drugs of abuse do not appear to directly modulate the function of these kinases. In the case of alcohol, there are some data indicating alcohol inhibition of PKC but only in a highly reduced in vitro system using artificial lipid membranes and purified proteins. 278 Convincing evidence for in vivo activation by intoxicating doses of ethanol is lacking however.
The protein kinases reviewed here have numerous downstream effects resulting in changes in gene transcription and protein synthesis that contribute to long-term changes in neural networks involved in addiction-related behavior. Several general conclusions may be drawn regarding the role of protein kinases in behavior related to drugs of abuse. Inhibition of ERK and CaMKII may be beneficial in reducing relapse for psychostimulants and opiates. For most drugs of abuse, inhibition of PKA decreases both drug self-administration and signs of drug withdrawal. For ethanol, however, increasing PKA activity in the central amygdala decreases self-administration and withdrawalinduced anxiety, and these responses may be mediated by increased expression of NPY and BDNF in that brain region. In contrast, deletion of PKCε increases sensitivity to ethanol and morphine and markedly decreases ethanol self-administration. Cdk5 appears to negatively regulate responding for cocaine and cocaine reward, suggesting that strategies designed to activate Cdk5 may be useful to treat cocaine addiction. Although Fyn appears to contribute to acute tolerance to the intoxicating effects of ethanol, data on Fyn regulation of ethanol self-administration remain inconclusive. Overall, protein kinase modulation of drug dependence, self-administration, and reward depends on the drug being studied and on the brain region in which the kinase is expressed and modulated.
Given these generalizations, it might seem beneficial to develop inhibitors of ERK, PKA, CaMKII, and PKCε to treat addiction. For PKCε this may be a reasonable approach since PKCε knockout mice are viable and show few phenotypes that raise the specter of serious side effects resulting from use of a PKCε inhibitor. However, ERK, CaMKII, and PKA are multifunctional kinases and the likelihood of inhibitors producing serious side effects is high. An alternative to modulating these kinases directly is to manipulate the signaling pathways in which they function. One approach is to develop drugs that regulate upstream activators or downstream effectors of these kinases. For example, A2a receptors activate PKA, and A2a antagonists decrease alcohol consumption in some models. 279 Likewise NPY, whose expression is increased by PKA, diminishes alcohol consumption when overexpressed in transgenic mice. 280 Since NPY-Y2 receptors act as autoreceptors that decrease NPY release, the use of NPY-Y2 antagonists has been explored as a strategy to reduce drinking in rodents. In rats the NPY-Y2 antagonist BIIE0246 reduces alcohol consumption, especially in animals with a history of ethanol dependence resulting from exposure to ethanol vapor. 281 In addition to manipulating upstream receptors and downstream molecules in kinase signaling cascades, another approach involves identifying direct kinase substrates in the hope that some will be useful targets for pharmaceutical development. Unfortunately, for most kinases this has been a difficult task and progress has been limited. Traditionally, kinase Figure 2 . The use of analog-sensitive kinases can facilitate substrate identification. The analog-sensitive kinase (as-kinase) is designed to incorporate ATP-γS analogs that have a bulky side group ( * ATP-γS). Native kinases can incorporate normal ATP-γS but cannot utilize the * ATP-γS. Substrates phosphorylated by the as-kinase can be identified by alkylation with para-nitrobenzylmesylate (PNBM) to create an epitope that is recognized by antibodies specific for the thiophosphate ester tag. The substrates can be isolated by immunoprecipitation or immunoaffinity purification and analyzed by mass spectrometry. Adapted from Reference 276. substrates have been identified pharmacologically using kinase activators or inhibitors. The specificity of these drugs can be problematic and the results of such studies often fail to identify a kinase substrate. 282 However, Shokat and colleagues 283 have promoted a novel chemicalgenetics approach to identify kinase substrates that target the structurally conserved purinebinding pocket found in all kinases. The strategy involves generating mutant alleles that can use ATP analogs in addition to ATP to phosphorylate substrate proteins. The mutation creates a "hole" in the pocket by replacing a conserved bulky amino acid with a smaller residue (Fig. 2) . ATP analogs ( * ATP) possessing a side group "bump" designed to fit into the hole can be used to identify substrates specific to the analog-sensitive (as) kinase mutant. Specificity for the mutant kinase is achieved because wild-type kinases cannot efficiently use the ATP analogs as phosphate donors. To fa-cilitate the identification and purification of substrates, * ATP-γS can be used instead of * ATP to label kinase substrates. This results in the transfer of a thiophosphate group onto the target substrate residue instead of a phosphate group. Thiophosphorylated residues can then be alkylated by para-nitrobenzylmesylate to create an epitope that is recognized by specific antibodies. The tagged substrates can be detected by western blot analysis and isolated by immunoprecipitation or immunoaffinity purification for detection by mass spectrometry. The approach has been successfully used to identify direct substrates of kinases. 283 In our view, as-kinases could be extremely useful in isolating distinct kinase substrates phosphorylated in response to drugs of abuse. The hope is that some of these substrates will prove to be targets for the development of useful agents to treat substance abuse in the future. 
